CHICAGO, Dec. 8, 2022 /PRNewswire/ — Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint […]
Author: Ken Dropiewski
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran)
– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – […]
Bristol Myers Squibb Announces Dividend Increase
NEW YORK–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on February 1, 2023 to stockholders of record at the close of […]
Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1 TITUSVILLE, N.J., Dec. 9, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing […]
EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards’ chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company’s Annual Meeting […]
Eko Named to 2022 CB Insights Digital Health 150
Eko’s AI-powered smart stethoscopes recognized for innovation in heart disease detection three years in-a-row OAKLAND, Calif., Dec. 8, 2022 /PRNewswire/ — Eko, a digital health company applying machine learning in the fight against heart and lung disease, today announced that it was named to the 2022 CB Insights Digital Health 150 list. This is […]
Qardio Celebrates 10 Years of Setting a New Standard for Remote Care
The brand continues to provide connected care with predictive insight for a changing world. SAN FRANCISCO, Dec. 8, 2022 /PRNewswire/ — Qardio, a leader in connected care with predictive insight for a changing world, is proud to be celebrating 10 years of disruptive technology. Founded in 2012, Qardio provides smart, connected wellness […]
Provident Healthcare Partners Advises Southwest Cardiovascular Associates in its Partnership with Cardiovascular Associates of America
BOSTON and NEW YORK, Dec. 8, 2022 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Southwest Cardiovascular Associates (“SWCVA” or “Company”) in its partnership with Cardiovascular Associates of America (“CVAUSA”), a portfolio company of Webster Equity Partners. SWCVA provides interventional and diagnostic cardiology services throughout its three-location footprint […]
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. […]
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events
Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or who are at, high risk for atherosclerotic cardiovascular disease (ASCVD) with elevated LDL-C levels1,2 The results position bempedoic acid as the […]
Recent
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
Popular
- No commented posts yet